Would you consider offering adjuvant Olaparib to a patient with early stage triple negative breast cancer, cT3N0, ypT1aN0, with BRCA VUS who has residual disease after neoadjuvant KEYNOTE-522 regimen?

Patients with TNBC and residual disease have several options. As trials of different approaches ran roughly concurrently, we lack data on how/when to combine, sequence, or choose. The capecitabine and olaparib trials did not include patients on IO therapy that would continue to the adjuvant setting....